Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
Merck & Co and Bayer’s vericiguat was deemed another “win” for heart failure at a medical conference this weekend. But widespread use looks unlikely.
A negative reaction to positive migraine data sends Biohaven down.
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Phase III data for Obseva's uterine fibroid project linzagolix need to prove its safety, while Inventiva tests its pan-PPAR agonist lanifibranor in Nash.
Digital health is a core focus for Philips. Might more acquisitions be on the way?
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
Two acquisitions of cell therapy companies could take them in almost opposite directions.
As Smiths Group delays its split partly so it can focus on ventilator production, the US FDA grants emergency authorisation to other breathing devices to treat Covid-19.
A Vantage analysis of FDA decisions expected in the next month and how the ongoing Covid-19 pandemic could affect these.